← Browse by Condition
Medical Condition

glioblastoma idh wildtype

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for glioblastoma idh wildtype sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma idh wildtype Clinical Trials

How many clinical trials are currently recruiting for glioblastoma idh wildtype?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for glioblastoma idh wildtype, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for glioblastoma idh wildtype?
glioblastoma idh wildtype research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a glioblastoma idh wildtype clinical trial?
Eligibility criteria for glioblastoma idh wildtype trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Erasmus Medical Center 1 trial
Jasper Gerritsen 1 trial
Mayo Clinic 1 trial
Jonsson Comprehensive Cancer Center 1 trial
Cure 51 1 trial

Recruiting Clinical Trials

NCT06273176
Recruiting
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Enrollment
225 pts
Location
United States, Belgi...
Sponsor
Erasmus Medical Center
View Trial →
NCT06118723
Recruiting
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Enrollment
784 pts
Location
United States, Belgi...
Sponsor
Jasper Gerritsen
View Trial →
NCT07301268 Phase 2
Recruiting
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Enrollment
36 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT07089641 Phase 1
Recruiting
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Enrollment
50 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
View Trial →
NCT06160596
Recruiting
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Enrollment
1,020 pts
Location
France
Sponsor
Cure 51
View Trial →

Related Conditions

glioblastoma (3) astrocytoma malignant (2) brain neoplasms (2) brain neoplasms adult (2) recurrent glioblastoma idh wildtype (2) recurrent gliosarcoma (2) resectable glioblastoma (2) glioblastoma multiforme of brain (1) brain neoplasms adult malignant (1) recurrent adult brain tumor (1) recurrent glioblastoma (1) high grade glioma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology